Prevalence, clinical and virological characteristics and short‐term prognosis of hepatitis delta infection among patients with HIV/HBV in Nouakchott, Mauritania

Abstract

AbstractPatients living with HIV infection (PLWH) are at risk of acquiring HBV and HDV. The present study aimed to determine the prevalence and characteristics of HIV–HDV–HBV tri‐infection in comparison with HIV–HBV coinfection and to estimate severities and outcomes of associated liver diseases in Mauritanian PLWH. Two‐hundred‐ninety‐two consecutive HBsAg‐positive PLWH were included (mean age: 37 years). Clinical data were recorded. Anti‐HDV antibodies, HBV and HDV viral loads (VLs) and genotype were determined. APRI, FIB‐4 and FibroScan were performed to evaluate the severity of liver disease. The anti‐HDV antibodies prevalence was 37% and HDV RNA was positive in 40.7% of patients. Genetic diversities were found with HDV genotype 1 (93%) and HBV genotypes D (42.5%) and E (38%). The HBV VL was detectable in 108 patients at inclusion, and mutations associated with HBV resistance were found in 20. For almost all variables studied, including FIB‐4 and APRI scores, no significant differences were found between anti‐HDV‐Ab positive or negative patients. FibroScan examination, which was performed in 110 patients at end‐of‐follow‐up showed higher, but NS values, in HDV positive patients. After a mean follow‐up of 24.55 ± 8.01 months (n = 217 patients), a highly significant worsening of APRI and FIB‐4 scores was found. Moreover, patients with HDV showed more severe liver disease progression despite an efficient therapy. In a substantial Mauritanian cohort of relatively young PLWH, we found high HDV prevalence and worsening liver disease. In high‐risk countries, screening for HDV and providing appropriate follow‐up and treatments are warranted in PLWH.